Development of β3-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans: Current status and future prospects

Drug Development Research

Volumn 51, Issue 2, 2000, Pages 80-93

  Weyer, Christian ^a,c   De Souza, Christopher J ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

3 adrenoceptor; Insulin sensitizers; Obesity; Pharmacotherapy; Thermogenic drugs

Indexed keywords

4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHOXY]PHENYLACETIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 4 [3 [BIS(BETA HYDROXYPHENETHYL)AMINO]BUTYL]BENZAMIDE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; AJ 9677; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CP 331684; INSULIN; L 755507; L 757793; L 770644; LIPID; LY 377604; RO 40 2148; RO 402148; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETES CONTROL; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIPID OXIDATION; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL; PRIMATE; REVIEW; SPECIES DIFFERENCE; TACHYCARDIA; TREMOR; WEIGHT REDUCTION;

EID: 0034523364     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200010)51:2<80::AID-DDR4>3.0.CO;2-E     Document Type: Review

References (1)

1. 3-adrenergic receptor gene with body mass index. Int J Obes 22:559-566.